VGLL2抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human kidney tissue lysate, Primary antibody: P09285(VGLL2 Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09285(VGLL2 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

VGLL2 (Vestigial-like protein 2) is a member of the VGLL family of transcriptional co-regulators, which play roles in modulating gene expression by interacting with transcription factors such as TEAD (TEA domain) proteins. These interactions are critical for regulating developmental pathways, including the Hippo signaling cascade, which governs cell proliferation, differentiation, and organ size. VGLL2 is particularly implicated in muscle development, tissue regeneration, and cancer progression. Studies suggest its involvement in sarcomas, breast cancer, and other malignancies, where it may act as either an oncogene or tumor suppressor depending on context.

VGLL2 antibodies are essential tools for detecting and quantifying VGLL2 protein expression in research applications like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies are typically generated using recombinant VGLL2 protein fragments or synthetic peptides as immunogens, yielding polyclonal or monoclonal variants. Specificity is validated through knockdown/knockout controls or competitive assays to ensure minimal cross-reactivity with homologous proteins like VGLL1 or VGLL3.

Research utilizing VGLL2 antibodies has shed light on its role in embryogenesis, muscle differentiation, and cancer biology. For instance, elevated VGLL2 expression correlates with poor prognosis in certain cancers, highlighting its potential as a biomarker or therapeutic target. Continued exploration of VGLL2's molecular mechanisms may advance understanding of developmental disorders and inform targeted cancer therapies.